At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed Glioblastoma Multiforme
- ✓Measurable tumor by MRI scan performed within two weeks prior to study entry, with tumor at least 5 mm
- ✓Subtotal resection or biopsy only (not gross total resection)
- ✓Age 18 years and over
- ✕Brain stem tumor
- ✕Prior chemotherapy
- ✕Prior radiotherapy
- ✕Prior immunotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Glioblastoma Multiforme of Brain. Completed, enrolled 40 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme.
Study Details
Timeline
Interventions
Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.